A Phase 1 Study of DB-67 (7-t-butyldimethysily1-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies

Grants and Contracts Details

StatusFinished
Effective start/end date10/25/062/28/10

Funding

  • Arno Therapeutics Inc: $330,660.00